Large molecule conjugation modification Dulaglutide Dulaglutide is a long-acting GLP-1 receptor agonist that employs Fc-fusion protein technology to achieve prolonged systemic exposure
Yes, discounts are available based on order quantity
- 7
Once approved, coverage will likely follow the same rules as Wegovy requiring BMI criteria, documentation, and prior authorization
While we anticipate retatrutide being a strong option for many people seeking weight loss, it may be particularly useful for anyone who falls into one or more of these categories: Didnt respond to earlier GLP-1 drugs like Wegovy, Ozempic, Rybelsus, Liraglutide, Zepbound, Mounjaro, etc Plateaued with other GLP-1s but still havent met your target weight Have a large body percentage of weight to lose (20% or more) Retatrutide is currently undergoing clinical trials necessary for it to obtain FDA approval (which is anticipated by summer) , so it's not yet available to be prescribed